Where BioCryst Pharma Stands With Analysts
Portfolio Pulse from Benzinga Insights
BioCryst Pharma (NASDAQ:BCRX) has received updated analyst ratings in the last quarter, with 1 bullish and 3 somewhat bullish ratings. The average 12-month price target for BCRX is $10.5, with a high of $12.00 and a low of $10.00, marking a 16.67% increase from the previous target of $9.00. Analysts base their ratings on financial predictions and company performance metrics.
November 20, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst Pharma has received mostly positive ratings from analysts, with an increased average price target of $10.5, suggesting a bullish outlook.
The positive analyst ratings and increased price target for BCRX indicate a bullish sentiment, which could lead to a short-term increase in the stock price as investors react to the optimistic outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100